Testosterone for Women

"In my practice in Philadelphia, women bring this up almost every week. A friend got pellets and felt amazing, or an article promised testosterone would fix the fatigue and the flatness of midlife. I understand the appeal. My job is to tell you the honest version: there is one thing testosterone has been shown to help in women, it helps modestly, and everything else being sold is still a hope, not a proven result. When the evidence is thin, I would rather say so than sell you a story."

Testosterone gets talked about as a men's hormone, but it is the most abundant sex hormone in a woman's bloodstream. Women circulate more testosterone than estradiol by concentration, even though a woman's testosterone sits far below a man's. So the question is fair: if it is there, and it falls with age, should you replace it? The answer the evidence gives is narrow and worth understanding before you spend money on a treatment or a pellet that cannot be undone.

Is testosterone a women's hormone?

Yes, testosterone is a women's hormone, and by blood concentration it is the most abundant sex hormone women make. The ovaries and the adrenal glands produce it. Levels peak in the 20s and drift downward with age, so that a woman in her 40s often carries roughly half the testosterone she did 2 decades earlier. That decline is gradual and mostly a feature of normal aging.

The sharp drop is different. When the ovaries are surgically removed (an oophorectomy, sometimes done alongside a hysterectomy), a major source of testosterone disappears overnight rather than fading over years. Women who go through surgical menopause this way can feel the change more abruptly than women who reach menopause naturally. That group is where the testosterone conversation is most worth having.

What does the evidence support testosterone doing for women?

The evidence supports 1 use: treating postmenopausal women who have hypoactive sexual desire disorder, which means low sexual desire that truly distresses them. This is not about a number on a lab report. It is about desire that has dropped in a way that bothers the woman herself and is not explained by relationship strain, depression, medication side effects, or pain.

The authority here is the 2019 Global Consensus Position Statement on the use of testosterone therapy for women, written by Davis and colleagues and endorsed by a long list of international menopause and endocrine societies. That panel read the randomized trials and concluded that low-dose transdermal testosterone modestly improves sexual desire, arousal, orgasm, and pleasure in postmenopausal women with this condition, and lowers the personal distress that comes with it. The systematic review behind that statement, published by Islam and colleagues in The Lancet Diabetes & Endocrinology the same year, pooled the trial data and found the same pattern.

So the honest headline is this: the benefit is real, it is specific to postmenopausal women with distressing low desire, and it is modest. That is the whole of what the trials support.

What does testosterone not reliably do for women?

Testosterone has not been shown to reliably improve energy, mood, thinking, muscle, bone, or the broad promise of "vitality" in women. The same 2019 global consensus that endorsed testosterone for low desire looked hard at these other uses and found the evidence insufficient to recommend it for any of them. That is a careful phrase, and it matters. It does not mean testosterone has been proven useless for energy or mood. It means the studies either have not been done well enough, or have not shown a clear effect, so no responsible clinician can promise those outcomes.

This is where most of the marketing lives, and where I part ways with it. If a program is selling testosterone to women for fatigue, brain fog, weight, or anti-aging, it is selling ahead of the science. The compound might help some women in ways trials have not captured yet, but you deserve to know you are trying something unproven, not buying a settled result. The consensus was also clear that there is not enough data to recommend testosterone for premenopausal women at all.

Why is there no FDA-approved testosterone product for women?

There is no testosterone product approved by the FDA for women in the United States. Products designed for women have come and gone over the years, and none cleared the bar of long-term safety data the agency wanted. So when testosterone is prescribed to a woman here, it is always off-label, meaning a clinician is using a medication approved for men in a carefully reduced dose for a use the label does not list.

The dose is the part that surprises people. A woman's target is roughly a tenth of a typical male dose. In practice that often means a small, measured amount of a testosterone gel or cream made for men, or a compounded cream, applied so that blood levels land back in the normal range for a healthy younger woman and no higher. Off-label is not a loophole or a red flag on its own. It is how testosterone is used for women across most of the world. But because the margin between a helpful dose and a level that causes side effects is small, the precision of the dosing and the monitoring behind it become the whole game.

How is testosterone dosed and monitored safely in women?

Testosterone is dosed safely in women by aiming for the normal premenopausal female range and never going above it. The plan starts low, moves slowly, and is guided by lab work rather than guesswork. Before starting, we check a baseline total testosterone and SHBG (the protein that binds testosterone) so we can estimate the free, active fraction. After starting, we recheck within the first 1 to 2 months and then periodically, watching that the level stays in range.

The failure mode to avoid is a supraphysiologic level, meaning testosterone pushed higher than a woman's body would ever make on its own. That is what produces the side effects people worry about: acne and unwanted facial or body hair growth are the common ones, and they usually ease when the dose comes down. Rarely, and mostly at high or sustained doses, women can develop voice deepening or clitoral enlargement, and those changes can be permanent. That risk is exactly why the goal is never a high level, and why a treatment we can dial back matters so much.

This is also where pellets come in. Testosterone pellets are implanted under the skin and release hormone for months, and the 2019 consensus specifically advises against them for women because they tend to deliver doses that overshoot the female range and cannot be adjusted or removed easily once they are in. Fishtown Medicine does not use pellets. We use low-dose transdermal forms that can be titrated up, dialed down, or stopped, because a treatment you can stop is a safer treatment when the therapeutic window is this narrow.

If desire has not improved after about 6 months at a properly dosed level, the right move is to stop rather than to keep pushing the dose higher.

Who should consider testosterone, and who should not?

The woman who should consider testosterone is postmenopausal, whether that came naturally or after her ovaries were removed, and is bothered by low sexual desire that the rest of her workup does not explain. Before testosterone enters the picture, the other causes get addressed first: vaginal dryness treated with local estrogen, thyroid and iron checked, sleep and mood looked at, medications reviewed (some antidepressants blunt desire), and estrogen therapy optimized if she is a candidate. Testosterone is the last piece added to a picture, not the first thing tried.

The women who should not use testosterone, at least not yet or not without specialist input, include premenopausal women, since the trial data are not there; women who are pregnant or breastfeeding; women with a history of hormone-sensitive cancer, without careful oncology input; and women seeking it purely for energy, weight, or anti-aging, where the evidence does not support the promise. Women who already struggle with significant acne or unwanted hair growth need extra caution, since testosterone can make both worse. And anyone unwilling to monitor with lab work is not a good candidate, because unmonitored testosterone in a woman is how the avoidable side effects happen.

How does Fishtown Medicine approach testosterone for women?

At Fishtown Medicine, the testosterone conversation for women follows the same honest pattern as every hormone conversation. The first job is a full workup, because low desire is rarely about testosterone alone. We look at estrogen and vaginal symptoms, thyroid, iron and ferritin, sleep, mood, medications, and the life context around desire, and we treat what we find.

If the picture still points to distressing low desire and the woman is postmenopausal, we talk through a trial of low-dose transdermal testosterone with clear expectations: the benefit is modest, we are aiming to restore a normal female level and no more, we will check labs at baseline and in follow-up, and we will stop at around 6 months if it is not helping. There are no pellets and no supraphysiologic dosing, and the practice will not sell testosterone for outcomes the evidence has not earned.

Because Fishtown Medicine is a mobile-first practice, that care happens through home visits across Greater Philadelphia plus secure messaging, phone, and video, so a woman adjusting a dose can ask a question the same week instead of waiting months for the next appointment. You can read more about the wider picture in the women's hormone care guide and the menopause care service page.

Scientific References and Sources

1. Davis SR, Baber R, Panay N, et al. (2019). "Global Consensus Position Statement on the Use of Testosterone Therapy for Women." Journal of Clinical Endocrinology and Metabolism, 104(10), 4660-4666.
2. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. (2019). "Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data." The Lancet Diabetes and Endocrinology, 7(10), 754-766.
3. Parish SJ, Simon JA, Davis SR, et al. (2021). "International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women." Climacteric, 24(6), 533-550.

Related at Fishtown Medicine

• Women's Hormone Health - the full picture of hormone care through perimenopause and menopause
• Low Libido - the many causes of low desire and how we find the one that fits
• Menopause Care in Philadelphia - how Dr. Ash approaches the menopause transition
• Hormone Optimization in Philadelphia - evidence-graded hormone care for women and men